FRANKFURT/BERLIN, May 18 (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Sturm served as chief financial officer before taking over as CEO in 2016 and has helped build the German company into a globally diversified healthcare group through a series of multi-billion dollar deals.

LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.

Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Index (PMI) data, output in the Healthcare sector is rising.

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") ...

LOS ANGELES, CA / ACCESSWIRE / May 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 1, 2017, and February 26, 2018, are encouraged to contact the firm before May 7, 2018, the lead plaintiff deadline.

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities during the period between March 1, 2017 through February 26, 2018, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/akrx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

NEW YORK, NY / ACCESSWIRE / May 4, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) who purchased shares between ...

Should You Keep an Eye on Akorn in 2018? Akorn (AKRX) used up $31.6 million in operating activities in 1Q18. In 1Q18, Akorn used $22.3 million in investing activities to acquire property, plants, and equipment.

Should You Keep an Eye on Akorn in 2018? In 1Q18, Akorn (AKRX) generated total revenue of $184 million compared to $253.4 million in 1Q17. Akorn’s ephedrine sulfate injection and lidocaine ointment saw sales erosion in 1Q18.

Should You Keep an Eye on Akorn in 2018? The Prescription Pharmaceuticals segment primarily consists of generic and branded prescription products. The Consumer Health segment consists of animal health and OTC (over-the-counter) products, both branded and private label.

NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akorn, Inc. ("Akorn" or the "Company") (AKRX) and certain of its officers, on behalf of shareholders who purchased Akorn securities during the period between March 1, 2017 through February 26, 2018, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...

LOS ANGELES, CA / ACCESSWIRE / May 3, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 1, 2017, and February 26, 2018, are encouraged to contact the firm before May 7, 2018, the lead plaintiff deadline.

NEW YORK, NY / ACCESSWIRE / May 3, 2018 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Illinois on behalf ...

German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (“Akorn” or the “Company”) (AKRX) and certain of its officers. The class action, filed in United States District Court, for the District of Illinois, Eastern Division, is on behalf of a class consisting of investors who purchased or otherwise acquired Akorn’s securities between March 1, 2017 through February 26, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn slid nearly 15 percent on Wednesday to end at $12.55 per share.

LOS ANGELES, CA / ACCESSWIRE / May 2, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion (3.5 billion pounds), according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn fell more than 8 percent in early trading Nasdaq on Wednesday to $13.57 per share.

NEW YORK, NY / ACCESSWIRE / May 2, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Akorn, Inc. ("Akorn") ...